Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 85(2): 287-93, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23702275

RESUMEN

An increasing number of protein therapies require chronic administration at high doses (>200 mg) by subcutaneous (sc) injection. Due to the injection volume limitation (<1.5 mL) associated with sc administration, high protein concentration formulations at or exceeding 100 mg/mL are required to achieve the dose. Development of a high concentration protein formulation can be challenging due to increased aggregation at higher concentration and/or chemical instability, which necessitates the development of lyophilized formulation for high protein concentration drug products. Unique challenges, such as long reconstitution time for a lyophilized high protein concentration drug product, can limit practical usage and commercial marketability of the product. In this paper, a systematic approach is presented to develop a lyophilized high concentration protein formulation. The focus is on achieving reasonable reconstitution times with multidisciplinary strategies. Many strategies have been shown to provide nominal improvement in reconstitution times, such as adding wetting agents in the diluents, incorporating high annealing steps in the lyophilization cycle and reconstituting under vacuum. The reconstitution strategy of reduced diluent volume, however, has enabled significant decrease in reconstitution time (4-7-fold) of lyophilized high protein concentration formulations.


Asunto(s)
Proteínas/química , Química Farmacéutica/métodos , Estabilidad de Medicamentos , Liofilización/métodos , Agentes Mojantes/química
2.
J Pharm Sci ; 102(3): 852-65, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23280943

RESUMEN

Understanding and mitigating particle formation in prefilled syringes are critical for ensuring stability of therapeutic proteins. In the current study, siliconized beads were used as a model for the silicone-water interface to evaluate subvisible particle formation and aggregation of a monoclonal antibody (IgG(1)). Agitation with siliconized beads greatly accelerated the formation of protein aggregates and particles, an effect that was enhanced at pH 7.4 relative to pH 5 and in the presence of 0.5 M sucrose or 150 mM NaCl. Aggregation and particle formation were minimal in samples agitated without siliconized beads or in quiescent samples with siliconized beads. At pH 5, 0.01% (w/v) polysorbate 20 substantially inhibited aggregation during agitation with siliconized beads, but had minimal protective effect at pH 7.4. Transient exposure of IgG(1) formulations to the silicone-water interface by flowing formulations through a column packed with siliconized beads led to the formation of subvisible particles, with increased levels observed at pH 7.4 compared to pH 5. Agitation of protein formulations in the presence of siliconized glass beads provides a model for baked-on silicone oil-water interface in prefilled syringes and a means by which to evaluate particle formation and aggregation during formulation screening.


Asunto(s)
Compuestos de Boro/química , Inmunoglobulina G/química , Silicatos/química , Siliconas/química , Agua/química , Vidrio/química , Concentración de Iones de Hidrógeno , Modelos Químicos , Tamaño de la Partícula , Polisorbatos/química , Aceites de Silicona/química , Cloruro de Sodio/química , Solubilidad , Sacarosa/química , Propiedades de Superficie , Jeringas
3.
Pharm Res ; 30(1): 131-9, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22907420

RESUMEN

PURPOSE: To study the impact of different process conditions and formulation compositions on metastable mannitol forms in protein formulations during lyophilization. METHODS: Mannitol was studied with and without other formulation components. A cryostage was used to mimic the different processing steps during lyophilization. The different mannitol forms were monitored and quantified with an in situ Raman spectroscopic method. In addition, a Raman imaging method was developed to characterize the spatial distribution of mannitol forms in final lyophilization samples from the freeze-drying stage. RESULTS: Amorphous mannitol was observed during fast cooling (10 °C/min) and with the addition of other formulation component. Amorphous mannitol crystallized into mainly δ and hemihydrate forms during annealing at -20 °C. Under vacuum without moisture, dried amorphous mannitol could transform to mainly α form at 45 °C and greater. The transformation mechanism of the hemihydrate mannitol was similar to that of amorphous form. CONCLUSION: Mannitol tends to crystallize into stable crystalline forms by itself, but the addition of lyoprotectant (e.g. sucrose) and protein helps stabilize the metastable forms (hemihydrate and amorphous). The metastable forms are capable of transforming into mixtures of different forms, with heat and moisture being the critical processing factors.


Asunto(s)
Liofilización , Manitol/química , Cristalización , Liofilización/métodos , Difracción de Polvo , Proteínas/química , Espectrometría Raman , Sacarosa/química , Difracción de Rayos X
4.
Pharm Res ; 30(4): 968-84, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23184227

RESUMEN

PURPOSE: To investigate the mechanism of IgG1 mAb stabilization after freeze-drying and the interdependence of protein structural preservation in the solid state, glassy state dynamics and long-term storage stability under different formulation conditions. METHODS: IgG1 mAb was formulated with mannitol at pH 3.0, 5.0, and 7.0 in the presence and absence of sucrose and stability was monitored over 1 year at different temperatures. Physical and covalent degradation of lyophilized formulation was monitored using SEC, CEX, and light obscuration technique. Secondary and tertiary structure of the protein in the solid state was characterized using FTIR and fluorescence spectroscopy respectively. Raman spectroscopy was also used to monitor changes in secondary and tertiary structure, while SS-NMR (1)H relaxation was used to monitor glassy state dynamics. RESULTS: IgG1 mAb underwent significant secondary structural perturbations at pH 3.0 and conditions without sucrose, while pH 5.0 condition with sucrose showed the least structural change over time. The structural changes correlated with long-term stability with respect to protein aggregate formation and SbVP counts. SS-NMR data showed reduced relaxation time at conditions that were more stable. CONCLUSIONS: Native state protein structural preservation and optimal solid-state dynamics correlate with improved long-term stability of the mAb in the different lyophilized formulations.


Asunto(s)
Anticuerpos Monoclonales/química , Excipientes/química , Inmunoglobulina G/química , Estabilidad Proteica , Almacenaje de Medicamentos , Liofilización , Manitol/química , Resonancia Magnética Nuclear Biomolecular , Estructura Secundaria de Proteína , Estructura Terciaria de Proteína , Espectroscopía Infrarroja por Transformada de Fourier , Sacarosa/química , Temperatura
5.
Curr Pharm Biotechnol ; 13(3): 471-96, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22283723

RESUMEN

Freeze drying, or lyophilization is widely used for biopharmaceuticals to improve the long term storage stability of labile molecules. This review examines general theory and practice of rational lyophilization of biopharmaceuticals. Formulation development involving the selection of appropriate excipients, their associated physical properties, and mechanism of action in achieving a stable drug product are primary considerations for a successful lyophilization program. There are several parameters considered critical on the basis of their relationship to lyophilization cycle development and protein product stability. This along with the importance of analytical methods to provide insight toward understanding properties of drug product stability and cake structure are discussed. Also, aspects of instability found in lyophilized biopharmaceutical products, their degradation pathways and control are elucidated. Finally, container-closure requirements and drug product handling are described in context of the caveats to avoid compromising drug product quality.


Asunto(s)
Proteínas/química , Proteínas/uso terapéutico , Química Farmacéutica/métodos , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Excipientes/química , Liofilización/métodos , Humanos
6.
Pharm Res ; 29(1): 209-24, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21845507

RESUMEN

PURPOSE: An IgG1 therapeutic monoclonal antibody showed an increase in acidic or pre-peak by cation exchange chromatography (CEX) at elevated temperatures, though stable at 2-8°C long-term storage in a liquid formulation. Characterization effort was undertaken to elucidate the degradants in CEX pre-peak and effect on biological activity. METHODS: Purified CEX fractions were collected and analyzed by peptide mapping, size exclusion, intact and reduced-alkylated reversed phase techniques. Biophysical characterization, isoelectric focusing and Isoquant analysis were also performed to determine nature of degradants. Bioassay and surface plasmon resonance experiments were performed to determine the impact on biological activity of the degradants. RESULTS: No major degradation due to oxidation, clipping or aggregation was detected; conformational differences between purified fractions observed were not significant. Sialic acid, N-terminal glutamine cyclization and glycation differences contributed to the CEX pre-peak in the mAb control sample; increase in CEX pre-peak at 25°C and higher was caused by additive degradation pathways of deamidation, related isomerization and clipping. CONCLUSIONS: The observed CEX pre-peak increase was caused by multiple degradations, especially deamidation and clipping. This elucidation of degradants in CEX peaks may apply to other therapeutic IgG1 monoclonal antibodies.


Asunto(s)
Anticuerpos Monoclonales/química , Cromatografía Liquida/métodos , Antígenos de Histocompatibilidad Clase I/química , Inmunoglobulina G/química , Receptores Fc/química , Animales , Asparagina/química , Ácido Aspártico/química , Células CHO , Química Farmacéutica , Cromatografía en Gel , Cromatografía por Intercambio Iónico , Cromatografía de Fase Inversa , Regiones Determinantes de Complementariedad/química , Cricetinae , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Glutamina/química , Glicosilación , Humanos , Inmunoglobulina G/análisis , Focalización Isoeléctrica , Espectrometría de Masas , Mapeo Peptídico , Temperatura , Tripsina/química
7.
J Pharm Sci ; 98(9): 3167-81, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19360857

RESUMEN

Silicone oil, which is used as a lubricant or coating in devices such as syringes, needles and pharmaceutical containers, has been implicated in aggregation and particulation of proteins and antibodies. Aggregation of therapeutic protein products induced by silicone oil can pose a challenge to their development and commercialization. To systematically characterize the role of silicone oil on protein aggregation, the effects of agitation, temperature, pH, and ionic strength on silicone oil-induced loss of monomeric anti-streptavidin IgG 1 antibody were examined. Additionally, the influences of excipients polysorbate 20 and sucrose on protein aggregation were investigated. In the absence of agitation, protein absorbed to silicone oil with approximately monolayer coverage, however silicone oil did not stimulate aggregation during isothermal incubation unless samples were also agitated. A synergistic stimulation of aggregation by a combination of agitation and silicone oil was observed. Solution conditions which reduced colloidal stability of the antibody, as assessed by determination of osmotic second virial coefficients, accelerated aggregation during agitation with silicone oil. Polysorbate 20 completely inhibited silicone oil-induced monomer loss during agitation. A formulation strategy involving optimization of colloidal stability of the antibody as well as incorporation of surfactants such as polysorbate 20 is proposed to reduce silicone oil-induced aggregation of therapeutic protein products.


Asunto(s)
Inmunoglobulina G/química , Estabilidad Proteica/efectos de los fármacos , Aceites de Silicona/farmacología , Estreptavidina/inmunología , Agua/química , Adsorción , Anticuerpos Monoclonales/química , Precipitación Química , Emulsiones/química , Concentración de Iones de Hidrógeno , Inmunoglobulina G/inmunología , Polisorbatos/química , Conformación Proteica/efectos de los fármacos , Cloruro de Sodio/química , Sacarosa/química , Temperatura de Transición
8.
Biophys J ; 96(1): 199-208, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19134476

RESUMEN

The complex, multistep aggregation kinetic and structural behavior of human recombinant interleukin-1 receptor antagonist (IL-1ra) was revealed and characterized by spectral probes and techniques. At a certain range of protein concentration (12-27 mg/mL) and temperature (44-48 degrees C), two sequential aggregation kinetic transitions emerge, where the second transition is preceded by a lag phase and is associated with the main portion of the aggregated protein. Each kinetic transition is linked to a different type of aggregate population, referred to as type I and type II. The aggregate populations, isolated at a series of time points and analyzed by Fourier-transform infrared spectroscopy, show consecutive protein structural changes, from intramolecular (type I) to intermolecular (type II) beta-sheet formation. The early type I protein spectral change resembles that seen for IL-1ra in the crystalline state. Moreover, Fourier-transform infrared data demonstrate that type I protein assembly alone can undergo a structural rearrangement and, consequently, convert to the type II aggregate. The aggregated protein structural changes are accompanied by the aggregate morphological changes, leading to a well-defined population of interacting spheres, as detected by scanning electron microscopy. A nucleation-driven IL-1ra aggregation pathway is proposed, and assumes two major activation energy barriers, where the second barrier is associated with the type I --> type II aggregate structural rearrangement that, in turn, serves as a pseudonucleus triggering the second kinetic event.


Asunto(s)
Proteína Antagonista del Receptor de Interleucina 1/química , Colorantes Fluorescentes , Humanos , Cinética , Microscopía Electrónica de Rastreo , Modelos Químicos , Modelos Moleculares , Multimerización de Proteína , Estructura Secundaria de Proteína , Proteínas Recombinantes/química , Espectroscopía Infrarroja por Transformada de Fourier , Temperatura
9.
Pharm Res ; 25(10): 2292-301, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18523875

RESUMEN

PURPOSE: To develop a novel multivariate curve resolution (MCR)-based Raman spectroscopic method to characterize and quantify five known mannitol solid-state forms in lyophilized protein formulations. MATERIALS AND METHODS: The multivariate quantitation method was developed based on second derivative Raman spectra of three anhydrous crystalline forms (alpha-, beta-, and delta-mannitol), a hemihydrate and an amorphous mannitol form. The method showed a 5% quantitation limit of mannitol forms in lyophilized model protein formulations. Binary mixtures of beta- and delta-mannitol combined with evaluation of the prediction residue were used for the method validation. X-ray powder diffractometry data was used to confirm the existence of mannitol forms in the sample. RESULTS: The various polymorphic forms of mannitol were characterized and quantified based on the Raman spectra of the existing pure forms, and the results are consistent with the X-ray powder diffraction data. This Raman method has been demonstrated for the application of monitoring and controlling of mannitol polymorphic forms in the lyophilized drug products during formulation and process development. It has implications in monitoring and improving the quality of the drug product. CONCLUSIONS: An MCR-Raman method has been developed for the quantitative determination of five different mannitol polymorphic forms in the presence of sucrose and protein.


Asunto(s)
Excipientes/química , Manitol/química , Proteínas/química , Espectrometría Raman , Tecnología Farmacéutica/métodos , Química Farmacéutica , Cristalografía por Rayos X , Liofilización , Difracción de Polvo
10.
Biochemistry ; 46(21): 6213-24, 2007 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-17480058

RESUMEN

Oxidation of methionine residues is involved in several biochemical processes and in degradation of therapeutic proteins. The relationship between conformational stability and methionine oxidation in recombinant human interleukin-1 receptor antagonist (rhIL-1ra) was investigated to document how thermodynamics of unfolding affect methionine oxidation in proteins. Conformational stability of rhIL-1ra was monitored by equilibrium urea denaturation, and thermodynamic parameters of unfolding (DeltaGH2O, m, and Cm) were estimated at different temperatures. Methionine oxidation induced by hydrogen peroxide at varying temperatures was monitored during "coincubation" of rhIL-1ra with peptides mimicking specific regions of the reactive methionine residues in the protein. The coincubation study allowed estimation of oxidation rates in protein and peptide at each temperature from which normalized oxidation rate constants and activation energies were calculated. The rate constants for buried Met-11 in the protein were lower than for methionine in the peptide with an associated increase in activation energy. The rate constants and activation energy of solvent exposed methionines in protein and peptide were similar. The results showed that conformational stability, monitored using the Cm value, has an effect on oxidation rates of buried methionines. The rate constant of buried Met-11 correlated well with the Cm value but not DeltaGH2O. No correlation was observed for the oxidation rates of solvent-exposed methionines with any thermodynamic parameters of unfolding. The findings presented have implications in protein engineering, in design of accelerated stability studies for protein formulation development, and in understanding disease conditions involving protein oxidation.


Asunto(s)
Proteína Antagonista del Receptor de Interleucina 1/química , Metionina/metabolismo , Humanos , Cinética , Oxidación-Reducción , Conformación Proteica , Desnaturalización Proteica , Pliegue de Proteína , Proteínas Recombinantes , Temperatura , Termodinámica
11.
J Pharm Sci ; 95(9): 2077-86, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16850397

RESUMEN

Mannitol hydrate is a metastable form produced during lyophilization. It is unstable, and therefore can undergo dehydration to release water to the surrounding environment at room temperature. The analysis of this form is challenging due to its thermodynamic instability. This study describes the development of a fast and non-invasive method to determine the mannitol hydrate and surface water content in a lyophilized product using near-infrared (NIR) spectroscopy. The mannitol hydrate was produced through lyophilization and characterized using XRPD, TGA, and NIR spectroscopy. Quantitative methods for hydrate and surface water were developed for NIR spectra with curve fitting and partial least square (PLS) regression models. The curve fitting method deconvoluted the NIR spectra into hydrate and surface water peaks and generated a calibration model by correlating pure spectra peak area to concentration. The standard error of prediction (SEP) for hydrate and surface water content were 0.65 and 0.40%, respectively. The PLS model developed for the same sample set was better than the curve fitting model; SEP = 0.50% for hydrate water and 0.22% for surface water, respectively. The methods can be used to monitor the formation and stability of mannitol hydrate in mannitol-containing formulations during the lyophilization process.


Asunto(s)
Manitol/química , Interpretación Estadística de Datos , Liofilización , Modelos Químicos , Soluciones Farmacéuticas , Reproducibilidad de los Resultados , Espectroscopía Infrarroja Corta , Propiedades de Superficie , Termogravimetría , Agua/química , Difracción de Rayos X
12.
J Pharm Sci ; 95(7): 1480-97, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16729274

RESUMEN

Antimicrobial preservatives (e.g., benzyl alcohol), which are required in multidose formulations, can induce protein aggregation. In this study, the mechanism of benzyl alcohol-induced aggregation of recombinant human granulocyte colony-stimulating factor (rhGCSF) was investigated by determining the effects of temperature, pH, and sucrose on this process. rhGCSF was incubated at 25 and 37 degrees C and at pH 7.0 (phosphate-buffered saline, PBS) and pH 3.5 (HCl). Benzyl alcohol (0.9% w/v) accelerated aggregation of rhGCSF at pH 7.0, an effect that was much greater at 37 degrees C than at 25 degrees C and partially counteracted by 1.0 M sucrose. At pH 3.5, benzyl alcohol did not induce aggregation of rhGCSF. Spectroscopic studies showed that 0.9% benzyl alcohol altered the tertiary structure of rhGCSF at both pH, without detectably altering secondary structure. Structural perturbation was greater at 37 degrees C than at 25 degrees C. At both pH 7.0 and 3.5, the hydrogen-deuterium (H-D) exchange rate for rhGCSF was increased by 0.9% benzyl alcohol. Sucrose (1.0 M) partially counteracted the benzyl alcohol-induced perturbation of tertiary structure and the increase in H-D exchange rate. Thus, benzyl alcohol accelerates aggregation of rhGCSF at pH 7.0, because it favors partially unfolded aggregation-prone conformations of the protein. Sucrose partially counteracts benzyl alcohol-induced rhGCSF aggregation by shifting the molecular population away from these species and towards more compact conformations. We postulate that the absence of aggregation at pH 3.5, even with benzyl alcohol-induced structural perturbation, is due to the unfavorable energetics of intermolecular interactions (i.e., colloidal stability) between rhGCSF molecules at this pH.


Asunto(s)
Alcohol Bencilo/química , Factor Estimulante de Colonias de Granulocitos/química , Sacarosa/química , Cromatografía en Gel , Dicroismo Circular , Medición de Intercambio de Deuterio , Humanos , Concentración de Iones de Hidrógeno , Pliegue de Proteína , Estructura Secundaria de Proteína , Estructura Terciaria de Proteína , Proteínas Recombinantes , Espectrofotometría Infrarroja , Temperatura
13.
J Pharm Sci ; 95(1): 126-45, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16315222

RESUMEN

Understanding the intermolecular products of antibodies as a consequence of host-cell expression, aging, and heat-stress can be insightful especially when it involves the development of a stable biopharmaceutical product. The dimerized form of Epratuzumab (an IgG(1) antibody) with a molecular mass of approximately 300 kDa (twice the monomer antibody molecular weight of approximately 150 kDa) was examined to gain a better perspective of its properties pertaining to structure and activity. The nascent dimer was shown to partially dissociate upon incubation at 30 degrees C and 37 degrees C, exhibit no discernable alteration of structure (i.e., secondary or tertiary structure based on CD and 2nd derivative UV spectroscopy), have approximately 70% covalent forms (based upon CE-SDS results) and manifest twofold higher activity relative to the active monomer form (on a weight basis the dimer and monomer have equal activity). Interestingly, these properties were not attributed to a single dimer species, but rather to a more complex dimer assembly. The Epratuzumab dimer was digested with papain to reveal three uniquely dimerized aggregates. The relative molar distribution of Fab:Fab, Fc:Fc, and Fab:Fc was found to be 4:3:8, respectively. The data suggest that all three predominantly covalent dimer adducts are capable of full activity, shedding light on their complex nature and showing that their target specificity was unaltered. ESI-MS data indicated the presence of remnant levels of noncovalent dimers for all three dimerized forms. Material aged at 37 degrees C exhibited a similar papain digest molar distribution of the three dimerized forms, except with enhanced chemical heterogeneity and an increase in covalent forms to approximately 84%.


Asunto(s)
Anticuerpos Monoclonales/química , Anticuerpos Monoclonales Humanizados , Antineoplásicos/química , Dimerización , Papaína/química , Temperatura
14.
J Pharm Sci ; 93(12): 3076-89, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15514986

RESUMEN

Benzyl alcohol, an antimicrobial preservative, accelerates aggregation and precipitation of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in aqueous solution. The loss of native monomer during incubation at 37 degrees C was determined by analysis of sample aliquots with size exclusion high performance liquid chromatography (SE-HPLC). Benzyl alcohol caused minor perturbation of the tertiary structure of the protein without changing its secondary structure, documenting that the preservative caused a minor shift in the protein molecular population toward partially unfolded species. Consistent with this conclusion, in the presence of benzyl alcohol the rate of H-D exchange was accelerated and the fluorescence of 1-anilinonaphthalene-8-sulfonic acid in the presence of rhIL1ra was increased. Benzyl alcohol did not alter the free energy of unfolding based on unfolding experiments in urea or guanidine HCl. With differential scanning calorimetry it was determined that benzyl alcohol reduced the apparent Tm of rhIL-1ra, but this effect occurred because the preservative lowered the temperature at which the protein aggregated during heating. Isothermal calorimetry documented that the interaction of benzyl alcohol with rhIL-1ra is relatively weak and hydrophobically driven. Thus, benzyl alcohol accelerates protein aggregation by binding to the protein and favoring an increase in the level of partially unfolded, aggregation-competent species. Sucrose partially inhibited benzyl alcohol-induced aggregation and tertiary structural change. Sucrose is preferentially excluded from the surface of the protein, favoring most compact native state species over expanded aggregation-prone forms.


Asunto(s)
Alcohol Bencilo/farmacología , Proteínas Recombinantes/metabolismo , Sialoglicoproteínas/metabolismo , Humanos , Proteína Antagonista del Receptor de Interleucina 1 , Receptores de Interleucina-1/antagonistas & inhibidores , Receptores de Interleucina-1/metabolismo , Proteínas Recombinantes/análisis , Sialoglicoproteínas/análisis , Soluciones , Agua/metabolismo
15.
J Pharm Sci ; 93(3): 684-96, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14762907

RESUMEN

Optimal storage stability of a protein in a dry formulation depends on the storage temperature relative to the glass transition temperature (T(g)) of the dried formulation and the structure of the dried protein. We tested the hypothesis that optimizing both protein structure and T(g)--by freeze-drying recombinant human interleukin-11 (rhIL-11) with mixtures of disaccharides and hydroxyethyl starch (HES)--would result in increased storage stability compared with the protein lyophilized with either disaccharide or hydroxyethyl starch alone. The secondary structure of the protein in the dried solid was analyzed immediately after lyophilization and after storage at elevated temperatures by infrared spectroscopy. After rehydration, aggregation was monitored by size exclusion chromatography. Oxidation levels and cleavage products were quantified by reversed-phase chromatography. For the formulation with HES alone, which has a relatively high T(g), storage stability of rhIL-11 was poor, because HES failed to inhibit lyophilization-induced unfolding. The sugar formulations inhibited unfolding, and had intermediate T(g) values and storage stabilities. Addition of hydroxyethyl starch to sucrose or trehalose increased T(g) without affecting the capacity of the sugar to inhibit protein unfolding during lyophilization. Optimal storage stability of lyophilized rhIL-11 was achieved by using a mixture of disaccharide and polymeric carbohydrates.


Asunto(s)
Disacáridos/química , Derivados de Hidroxietil Almidón/química , Interleucina-11/química , Disacáridos/análisis , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Liofilización/métodos , Humanos , Derivados de Hidroxietil Almidón/análisis , Interleucina-11/análisis , Proteínas Recombinantes/análisis , Proteínas Recombinantes/química
16.
Pharm Res ; 20(9): 1325-36, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14567625

RESUMEN

Irreversible protein aggregation is problematic in the biotechnology industry, where aggregation is encountered throughout the lifetime of a therapeutic protein, including during refolding, purification, sterilization, shipping, and storage processes. The purpose of the current review is to provide a fundamental understanding of the mechanisms by which proteins aggregate and by which varying solution conditions, such as temperature, pH, salt type, salt concentration, cosolutes, preservatives, and surfactants, affect this process.


Asunto(s)
Proteínas/química , Solventes/química , Agua/química , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Concentración de Iones de Hidrógeno , Soluciones Farmacéuticas/química , Conformación Proteica , Pliegue de Proteína , Tensoactivos/química , Temperatura
17.
Protein Sci ; 12(5): 903-13, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12717013

RESUMEN

We studied the non-native aggregation of recombinant human granulocyte stimulating factor (rhGCSF) in solution conditions where native rhGCSF is both conformationally stable compared to its unfolded state and at concentrations well below its solubility limit. Aggregation of rhGCSF first involves the perturbation of its native structure to form a structurally expanded transition state, followed by assembly process to form an irreversible aggregate. The energy barriers of the two steps are reflected in the experimentally measured values of free energy of unfolding (DeltaG(unf)) and osmotic second virial coefficient (B(22)), respectively. Under solution conditions where rhGCSF conformational stability dominates (i.e., large DeltaG(unf) and negative B(22)), the first step is rate-limiting, and increasing DeltaG(unf) (e.g., by the addition of sucrose) decreases aggregation. In solutions where colloidal stability is high (i.e., large and positive B(22) values) the second step is rate-limiting, and solution conditions (e.g., low pH and low ionic strength) that increase repulsive interactions between protein molecules are effective at reducing aggregation. rhGCSF aggregation is thus controlled by both conformational stability and colloidal stability, and depending on the solution conditions, either could be rate-limiting.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos/química , Coloides , Dimerización , Estabilidad de Medicamentos , Humanos , Conformación Proteica , Desnaturalización Proteica , Proteínas Recombinantes/química , Soluciones , Espectroscopía Infrarroja por Transformada de Fourier , Termodinámica
18.
Biochemistry ; 42(3): 829-37, 2003 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-12534296

RESUMEN

Intraneuronal deposition of alpha-synuclein as fibrils and oxidative stress are both implicated in the pathogenesis of Parkinson's disease. We found that the critical rate-limiting step in nucleation of alpha-synuclein fibrils under physiological conditions is the oxidative formation and accumulation of a dimeric, dityrosine cross-linked prenucleus. Dimer formation is accelerated for the pathogenic A30P and A53T mutant alpha-synucleins, because of their greater propensity to self-interact, which is reflected in the smaller values of the osmotic second virial coefficient compared to that of wild-type synuclein. Our finding that oxidation is an essential step in alpha-synuclein aggregation supports a mechanism of Parkinson's disease pathogenesis in which the separately studied pathogenic factors of oxidative stress and alpha-synuclein aggregation converge at the critical step of alpha-synuclein dimer formation.


Asunto(s)
Proteínas del Tejido Nervioso/metabolismo , Enfermedad de Parkinson/metabolismo , Tirosina/análogos & derivados , Sustitución de Aminoácidos/genética , Cromatografía Líquida de Alta Presión , Reactivos de Enlaces Cruzados/metabolismo , Dimerización , Humanos , Concentración de Iones de Hidrógeno , Luz , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/ultraestructura , Concentración Osmolar , Presión Osmótica , Oxidación-Reducción , Estrés Oxidativo , Enfermedad de Parkinson/etiología , Enfermedad de Parkinson/patología , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Dispersión de Radiación , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Espectrofotometría Ultravioleta , Sinucleínas , Temperatura , Tirosina/metabolismo , alfa-Sinucleína
19.
Biochemistry ; 41(20): 6422-31, 2002 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-12009905

RESUMEN

We have investigated the aggregation of recombinant human granulocyte colony stimulating factor (rhGCSF), a protein that rapidly aggregates and precipitates at pH 6.9 and 37 degrees C. We observed that native monomeric rhGCSF reversibly forms a dimer under physiological conditions and that this dimeric species does not participate in the irreversible aggregation process. Sucrose, a thermodynamic stabilizer, inhibits the aggregation of rhGCSF. We postulate that sucrose acts by reducing the concentration of structurally expanded species, consistent with the hypothesis that preferential exclusion favors most compact species in the native state ensemble. Thermodynamic stability data from unfolding curves and hydrogen-deuterium exchange experimental results support the above hypothesis. Thus, the strategy of stabilizing the native state of the protein under physiological conditions using thermodynamic stabilizers, especially ligands binding with high affinity to the native state, is expected to protect against protein aggregation occurring under such nonperturbing solution conditions.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos/antagonistas & inhibidores , Factor Estimulante de Colonias de Granulocitos/química , Precipitación Química , Dicroismo Circular , Deuterio/química , Dimerización , Factor Estimulante de Colonias de Granulocitos/metabolismo , Factor Estimulante de Colonias de Granulocitos/ultraestructura , Humanos , Hidrógeno/química , Cinética , Desnaturalización Proteica , Pliegue de Proteína , Estructura Secundaria de Proteína , Proteínas Recombinantes , Soluciones , Espectrofotometría Infrarroja , Espectrofotometría Ultravioleta , Sacarosa/química , Propiedades de Superficie , Termodinámica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...